{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T09:05:59Z","timestamp":1791450359655,"version":"4.3.3"},"reference-count":29,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2021,3,22]],"date-time":"2021-03-22T00:00:00Z","timestamp":1616371200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI16\/01378"],"award-info":[{"award-number":["PI16\/01378"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI19\/01453"],"award-info":[{"award-number":["PI19\/01453"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["RD16\/0016\/0009"],"award-info":[{"award-number":["RD16\/0016\/0009"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CP15\/00132"],"award-info":[{"award-number":["CP15\/00132"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>The development of new strategic antimicrobial therapeutic approaches, such as drug repurposing, has become an urgent need. Previously, we reported that tamoxifen presents therapeutic efficacy against multidrug-resistant (MDR) Acinetobacter baumannii, Pseudomonas aeruginosa, and Escherichia coli in experimental infection models by modulating innate immune system cell traffic. The main objective of this study was to analyze the activity of N-desmethyltamoxifen, 4-hydroxytamoxifen, and endoxifen, three major metabolites of tamoxifen, against these pathogens. We showed that immunosuppressed mice infected with A. baumannii, P. aeruginosa, or E. coli in peritoneal sepsis models and treated with tamoxifen at 80 mg\/kg\/d for three days still reduced the bacterial load in tissues and blood. Moreover, it increased mice survival to 66.7% (for A. baumannii and E. coli) and 16.7% (for P. aeruginosa) when compared with immunocompetent mice. Further, susceptibility and time-kill assays showed that N-desmethyltamoxifen, 4-hydroxytamoxifen, and endoxifen exhibited minimum inhibitory concentration of the 90% of the isolates (MIC90) values of 16 mg\/L, and were bactericidal against clinical isolates of A. baumannii and E. coli. This antimicrobial activity of tamoxifen metabolites paralleled an increased membrane permeability of A. baumannii and E. coli without affecting their outer membrane proteins profiles. Together, these data showed that tamoxifen metabolites presented antibacterial activity against MDR A. baumannii and E. coli, and may be a potential alternative for the treatment of infections caused by these two pathogens.<\/jats:p>","DOI":"10.3390\/antibiotics10030336","type":"journal-article","created":{"date-parts":[[2021,3,22]],"date-time":"2021-03-22T11:13:26Z","timestamp":1616411606000},"page":"336","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Repurposing of the Tamoxifen Metabolites to Combat Infections by Multidrug-Resistant Gram-Negative Bacilli"],"prefix":"10.3390","volume":"10","author":[{"given":"Andrea","family":"Mir\u00f3-Canturri","sequence":"first","affiliation":[{"name":"Clinical Unit of Infectious Diseases, Microbiology and Preventive Medicine, University Hospital Virgen del Roc\u00edo, 41013 Seville, Spain"},{"name":"Institute of Biomedicine of Seville (IBiS), University Hospital Virgen del Roc\u00edo, CSIC, University of Seville, 41013 Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Ayerbe-Algaba","sequence":"additional","affiliation":[{"name":"Clinical Unit of Infectious Diseases, Microbiology and Preventive Medicine, University Hospital Virgen del Roc\u00edo, 41013 Seville, Spain"},{"name":"Institute of Biomedicine of Seville (IBiS), University Hospital Virgen del Roc\u00edo, CSIC, University of Seville, 41013 Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Vila-Dom\u00ednguez","sequence":"additional","affiliation":[{"name":"Clinical Unit of Infectious Diseases, Microbiology and Preventive Medicine, University Hospital Virgen del Roc\u00edo, 41013 Seville, Spain"},{"name":"Institute of Biomedicine of Seville (IBiS), University Hospital Virgen del Roc\u00edo, CSIC, University of Seville, 41013 Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel E.","family":"Jim\u00e9nez-Mej\u00edas","sequence":"additional","affiliation":[{"name":"Clinical Unit of Infectious Diseases, Microbiology and Preventive Medicine, University Hospital Virgen del Roc\u00edo, 41013 Seville, Spain"},{"name":"Institute of Biomedicine of Seville (IBiS), University Hospital Virgen del Roc\u00edo, CSIC, University of Seville, 41013 Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8166-5308","authenticated-orcid":false,"given":"Jer\u00f3nimo","family":"Pach\u00f3n","sequence":"additional","affiliation":[{"name":"Institute of Biomedicine of Seville (IBiS), University Hospital Virgen del Roc\u00edo, CSIC, University of Seville, 41013 Seville, Spain"},{"name":"Department of Medicine, University of Seville, 41009 Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9302-8384","authenticated-orcid":false,"given":"Younes","family":"Smani","sequence":"additional","affiliation":[{"name":"Clinical Unit of Infectious Diseases, Microbiology and Preventive Medicine, University Hospital Virgen del Roc\u00edo, 41013 Seville, Spain"},{"name":"Institute of Biomedicine of Seville (IBiS), University Hospital Virgen del Roc\u00edo, CSIC, University of Seville, 41013 Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,3,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Mir\u00f3-Canturri, A., Ayerbe-Algaba, R., del Toro, R., Pach\u00f3n, J., and Smani, Y. (2020). Tamoxifen repurposing to combat infections by multidrug-resistant Gram-negative bacilli. bioRxiv.","DOI":"10.1101\/2020.03.30.017475"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1128\/AAC.01640-12","article-title":"Adenylate kinase release as a high-throughput-screening-compatible reporter of bacterial lysis for identification of antibacterial agents","volume":"57","author":"Jacobs","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"11048","DOI":"10.1073\/pnas.1511751112","article-title":"Antagonism screen for inhibitors of bacterial cell wall biogenesis uncovers an inhibitor of undecaprenyl diphosphate synthase","volume":"112","author":"Farha","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"8369","DOI":"10.1038\/ncomms9369","article-title":"Tamoxifen augments the innate immune function of neutrophils through modulation of intracellular ceramide","volume":"6","author":"Corriden","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1128\/CMR.00064-16","article-title":"Polymyxins: Antibacterial Activity, susceptibility testing, and resistance mechanisms encoded by plasmids or chromosomes","volume":"30","author":"Poirel","year":"2017","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/nrc2683","article-title":"CYP2D6 and tamoxifen: DNA matters in breast cancer","volume":"9","author":"Hoskins","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1093\/jac\/dks050","article-title":"Diabetic murine models for Acinetobacter baumannii infection","volume":"67","author":"Luo","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e00140-17","DOI":"10.1128\/mBio.00140-17","article-title":"New mouse model for chronic infections by Gram-negative bacteria enabling the study of anti-infective efficacy and host-microbe interactions","volume":"8","author":"Pletzer","year":"2017","journal-title":"mBio"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Zuluaga, A.F., Salazar, B.E., Rodr\u00edguez, C.A., Zapata, A.X., Agudelo, M., and Vesga, O. (2006). Neutropenia induced in outbred mice by a simplified low-dose cyclophosphamide regimen: Characterization and applicability to diverse experimental models of infectious diseases. BMC Infect. Dis., 6.","DOI":"10.1186\/1471-2334-6-55"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1146\/annurev.micro.56.012302.160310","article-title":"Function of Pseudomonas porin in uptake and efflux","volume":"56","author":"Hancock","year":"2002","journal-title":"Ann. Rev. Microbiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/j.1469-0691.2007.01681.x","article-title":"Pseudomonas aeruginosa: Resistance and therapeutic options at the turn of the new millennium","volume":"13","author":"Mesaros","year":"2007","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e02272-18","DOI":"10.1128\/mBio.02272-18","article-title":"Repurposing estrogen receptor antagonists for the treatment of infectious disease","volume":"9","author":"Montoya","year":"2018","journal-title":"mBio"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Chen, F.C., Liao, Y.C., Huang, J.M., Lin, C.H., Chen, Y.Y., Dou, H.Y., and Hsiung, C.A. (2014). Pros and cons of the tuberculosis drugome approach-an empirical analysis. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0100829"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1186\/s12936-019-3012-7","article-title":"Tamoxifen activity against Plasmodium in vitro and in mice","volume":"18","author":"Weinstock","year":"2019","journal-title":"Malar. J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e00765-13","DOI":"10.1128\/mBio.00765-13","article-title":"Estrogen receptor antagonists are anti-cryptococcal agents that directly bind EF hand proteins and synergize with fluconazole in vivo","volume":"5","author":"Butts","year":"2014","journal-title":"mBio"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1128\/AAC.01564-08","article-title":"Antifungal activity of tamoxifen: In vitro and in vivo activities and mechanistic characterization","volume":"53","author":"Dolan","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Butts, A., Martin, J.A., DiDone, L., Bradley, E.K., Mutz, M., and Krysan, J. (2015). Structure-activity relationships for the antifungal activity of selective estrogen receptor antagonists related to tamoxifen. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0125927"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1021\/cb500828m","article-title":"Discovery of desketoraloxifene analogues as inhibitors of mammalian, Pseudomonas aeruginosa, and nape phospholipase d enzymes","volume":"10","author":"Scott","year":"2015","journal-title":"ACS Chem. Biol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1128\/jb.95.5.1520-1541.1968","article-title":"A 377 study of the Moraxella grouP. II. Oxidative negative species (genus Acinetobacter)","volume":"95","author":"Baumann","year":"1968","journal-title":"J. Bacteriol."},{"key":"ref_20","first-page":"572","article-title":"Genetic recombination in Pseudomonas aeruginosa","volume":"13","author":"Holloway","year":"1955","journal-title":"J. Gen. Microbial."},{"key":"ref_21","unstructured":"(2021). Escherichia coli (Migula) Castellani and Chalmers (ATCC\u00ae 25922\u2122). 1946 FDA strain Seattle [DSM 1103, NCIB 12210], American Type Culture Collection."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4464","DOI":"10.1128\/AAC.02708-15","article-title":"Efficacy of lysophosphatidylcholine in combination with antimicrobial agents against Acinetobacter baumannii in experimental murine peritoneal sepsis and pneumonia models","volume":"60","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_23","first-page":"4","article-title":"In vitro activity of 18 antimicrobial agents against clinical isolates of Acinetobacter spp.: Multicenter national study GEIH-REIPI-Ab 2010","volume":"31","author":"Bou","year":"2012","journal-title":"Enferm. Infecc. Microbiol. Clin."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.ijantimicag.2016.09.003","article-title":"First report of the plasmid-mediated colistin resistance gene mcr-1 in a clinical Escherichia coli isolate in Algeria","volume":"48","author":"Yanat","year":"2016","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Rodriguez Villodres, A., Alvarez Mar\u00edn, R., Dur\u00e1n Lobato, M., Pach\u00f3n Ib\u00e1\u00f1ez, M.E., Aznar, J., Pach\u00f3n D\u00edaz, J., Lepe, J.A., and Smani, Y. (2019, January 13\u201316). Overexpression of outer membrane protein A by Escherichia coli as a risk factor for mortality in bloodstream infection. Proceedings of the 29th European Congress of Clinical Microbiology and Infectious Diseases, Amsterdam, The Netherlands.","DOI":"10.2139\/ssrn.3445534"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"14683","DOI":"10.1038\/s41598-017-14972-y","article-title":"Combating virulence of Gram-negative bacilli by OmpA inhibition","volume":"7","author":"Varese","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_27","unstructured":"(2017, February 03). Jackson Website. Available online: https:\/\/www.jax.org\/research-and-faculty\/resources\/cre-repository\/tamoxifen#."},{"key":"ref_28","unstructured":"Clinical and Laboratory Standards Institute (2017). Performance Standards for Antimicrobial Susceptibility Testing (Twenty-Seventh Informational Supplement M100-S27, CLSI."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"26901","DOI":"10.1074\/jbc.M112.344556","article-title":"Platelet-activating factor receptor initiates contact of Acinetobacter baumannii expressing phosphorylcholine with host cells","volume":"287","author":"Smani","year":"2012","journal-title":"J. Biol. Chem."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/10\/3\/336\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:39:18Z","timestamp":1760161158000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/10\/3\/336"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,22]]},"references-count":29,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,3]]}},"alternative-id":["antibiotics10030336"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics10030336","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.03.30.017475","asserted-by":"object"}]},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,22]]}}}